Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

Molteni Deal Raises Valuation

http://s1.q4cdn.com/460208960/files/News/2017/Nov-29-2017_TTNP_Vandermosten.pdf

Interesting notes from Zacks:

"In its search for a European partner, Titan was focused on a company that has experience in the European market and that conforms to the regulatory environment for controlled substances. Molteni has developed a proprietary software system that provides critical infrastructure for tracking and maintenance of Schedule II and III substances. Molteni s familiarity with all of the varied requirements in each of the EU member states and their software system which makes it easy for customers to comply with the requirements have attracted a long term and loyal customer base. These attractive features supported Titan's selection of Molteni as partner for commercializing Probuphine."


And...

"The European market has been recognized to be approximately 10% the size of the US market for addiction treatment based on relative Suboxone sales in the two regions. In the EU market, our research identified approximately 1.3 million high-risk opioid users and about 644,000 of this population seeking treatment in 2016, the latter of which represents the addressable market. We see both population growth and number of addicts seeking treatment as stable over the forecast period."